".........derisking clinical development in the US". That's the message.
Every person connected to Cynata is an armchair expert on the FDA. "deficient process". Yet Cynata has NEVER started a P1, P2 or P3 trial in the US.
If the P2 trail for GVHD doesn't start, will you be surprised?
I mean, given what Cynata has stated and done and given the 'derisking' due to the 'deficient process' of MSB, how could the trial NOT commence, right?!
Yet, here we are.
Talking and doing - not the same thing.
Prepare yourself for a change of direction and reallocation of funds. Or just be shocked.
CYP Price at posting:
11.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)